ArticleThe Journal of clinical investigation1998
Pivotal role of TARC, a CC chemokine, in bacteria-induced fulminant hepatic failure in mice.
Article in The Journal of clinical investigation, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 140 citations in OpenAlex.
- Modulation of Chemokine Activity for Enhanced Angiogenesis and Tissue Regeneration in Chronic Wounds.International journal of molecular sciences · 2026Review
- Article
- Mimicking chronic alcohol effects through a controlled and sustained ethanol release device.Journal of biological engineering · 2024Article
- GPR120 induces regulatory dendritic cells by inhibiting HK2-dependent glycolysis to alleviate fulminant hepatic failure.Cell death & disease · 2021Article
- Evaluating the impact of hydroxychloroquine on mouse lymphocyte proliferation and cytokine productionSTAR protocols · 2021Article
- Inhibition of EZH2 ameliorates bacteria-induced liver injury by repressing RUNX1 in dendritic cells.Cell death & disease · 2020Article
- IL-17A Can PromoteFrontiers in immunology · 2019Article
- Tpl2 Protects Against Fulminant Hepatitis Through Mobilization of Myeloid-Derived Suppressor Cells.Frontiers in immunology · 2019Article
- Myeloid Cells and Chronic Liver Disease: a Comprehensive Review.Clinical reviews in allergy & immunology · 2018Review
- CCR4 Controls the Suppressive Effects of Regulatory T Cells on Early and Late Events during Severe Sepsis.PloS one · 2015Article
- Mesenchymal stem cells alleviate bacteria-induced liver injury in mice by inducing regulatory dendritic cells.Hepatology (Baltimore, Md.) · 2014Article
- A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma.Medical molecular morphology · 2013Article
- Exploring the abomasal lymph node transcriptome for genes associated with resistance to the sheep nematode Teladorsagia circumcincta.Veterinary research · 2013Article
- Inhibition of Glutaminyl Cyclases alleviates CCL2-mediated inflammation of non-alcoholic fatty liver disease in mice.International journal of experimental pathology · 2013Article
- Article
- Article
- CC chemokine receptor 4 contributes to innate NK and chronic stage T helper cell recall responses during Mycobacterium bovis infection.The American journal of pathology · 2011Article
- Neutralizing endogenous chemokines with small molecules. Principles and potential therapeutic applications.Pharmacology & therapeutics · 2010Review
- Neutralization of CXCL10 accelerates liver regeneration in carbon tetrachloride-induced acute liver injury.Medical molecular morphology · 2007Article
- Treatment with chondroitinase ABC alleviates bleomycin-induced pulmonary fibrosis.Medical molecular morphology · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thymus and activation-regulated chemokine (TARC) is a recently identified lymphocyte-directed CC chemokine which specifically chemoattracts T helper type 2 CD4(+) T cells in human. To establish the pathophysiological roles of TARC in vivo, we investigated whether a monoclonal antibody (mAb) against TARC could inhibit the induction of hepatic lesions in murine model using Propionibacterium acnes and lipopolysaccharide (LPS). P. acnes-induced intrahepatic granuloma formation in the priming phase is essential to the subsequent liver injury elicited by a low dose of LPS. The priming phase appears to be dominated by Th1 type immune responses determined by the profile of chemokine and chemokine receptor expression. TARC was selectively produced by granuloma-forming cells, and CC chemokine receptor 4 (CCR4)-expressing CD4(+) T cells migrated into the liver after LPS administration. In vivo injection of anti-TARC mAb just before LPS administration protected the mice from acute lethal liver damage, which was accompanied by a significant reduction of both CCR4 mRNA expression and IL-4 production by liver-infiltrating CD4(+) T cells. Moreover, both TNF-alpha and Fas ligand expressions in the liver were decreased by anti-TARC treatment. These results suggest that recruitment of IL-4-producing CCR4(+) CD4(+) T cells by granuloma-derived TARC into the liver parenchyma may be a key cause of massive liver injury after systemic LPS administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.